mr.sc. Ovanin - Rakić Ana, dr.med.

Similar documents
Understanding Your Pap Test Results

BC Cancer Cervix Screening 2015 Program Results. February 2018

Colposcopy. Attila L Major, MD, PhD

GYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital

Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two

EU guidelines for reporting gynaecological cytology

KLASIFIKACIJA CITOLO[KIH NALAZA VRATA MATERNICE»ZAGREB 2002«Modifikacija klasifikacija»zagreb 1990«i»NCI Bethesda system 2001«

Clinical Practice Guidelines June 2013

Making Sense of Cervical Cancer Screening

Is the HSIL Subclassification Cytologically Real and Clinically Justified?

Cervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens

The society for lower genital tract disorders since 1964.

Cervical Precancer: Evaluation and Management

Chapter 10: Pap Test Results

The Korean Journal of Cytopathology 13(1): 14-20, 2002

Management Algorithms for Abnormal Cervical Cytology and Colposcopy

Pap Reports. Of all women undergoing Papanicolaou (Pap) What Now? Women s Health. What has changed?

Cervical Screening for Dysplasia and Cancer in Patients with HIV

Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013

Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing

!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$

HKCOG GUIDELINES NUMBER 3 (revised November 2002) published by The Hong Kong College of Obstetricians and Gynaecologists

Pap Smear Adequacy Is the Assessing Criterion Including Endocervical Cells Really Valid?

Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary

Cervical Cancer Screening Update. Melissa Hartman, DO Women s Health

Manitoba Cervical Cancer Screening Program. Operations & Statistical Report and 2006

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

Pushing the Boundaries of the Lab Diagnosis in Asia

Cervical Cytology and HPV Test in Follow-up after Conisation or LLETZ

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

King s Research Portal

I have no financial interests to disclose.

GUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED

AGC Subclasses and Risk of Invasive Cancers

The prevalence and spectrum of atypical glandular cells in Dubai hospital: A local experience

HPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series

Glandular lesions in cervical cytology. Margareta Strojan Fležar Institute of Pathology Faculty of Medicine University of Ljubljana Slovenia

Eradicating Mortality from Cervical Cancer

Should Anal Pap Smears Be a Standard of Care in HIV Management?

ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests

Dysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.

Cervical Cancer : Pap smear

Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA

Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure

CERVIKALNA INTRAEPITELNA NEOPLAZIJA (CIN). USPOREDBA PATOHISTOLOŠKOG I PAPA NALAZA.

PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals

Beatrix Cochand-Priollet. An overview of terminologies in cervical cytology in Europe

Cytologic Follow-up in Patients with CIN Treated by LLETZ, Cold Knife Conization and Semm s Cold Coagulation

ICD-9-CM to ICD-10-CM DIAGNOSIS CODE MAPPING. Central Valley Public Health: Women's Way

ACGME Competency / Milestone Assessment. The Pap Test. Ricardo R. Lastra, MD Zubair W. Baloch, MD, PhD

European Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs

PAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE

Cytology of Cervical Intraepithelial Glandular Lesions

Improved National Croatian Diagnostic and Therapeutic Guidelines for Premalignant Lesions of the Uterine Cervix with Some Cost-Benefit Aspects

GLANDULAR LESIONS PITFALLS IN MANAGEMENT. Dr Li Wai Hon HKSCCP The 15 th Anniversary Symposium 10 December 2016

The ABCs of TBS. A Novice's Guide to the Bethesda System

chapter 4. The effect of oncogenic HPV on transformation zone epithelium

ANALYSES OF CERVICAL CANCER IN RAJKOT POPULATION

Managament of Abnormal Cervical Cytology and Histology

Comparative Study of Pap Smear Quality by using Ayre s Spatula versus Ayre s Spatula and Cytobrush Combination

Management of Abnormal Cervical Cytology and Histology

Lessons From Cases of Screened Women Who Developed Cervical Carcinoma

Citologija vrata maternice (Papa-test) terminologija i značaj u probiru za rak vrata maternice

Cervical Dysplasia and HPV

Mody. Atypical Glandular Cells(TBS 2001) Adenocarcinoma In Situ(TBS 2001)

Cervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH

Protocol for an integrated data request of test results from the laboratories of pathological anatomy

HPV Testing & Cervical Cancer Screening:

Becoming a colposcopist: Colposcope case studies

Long-Term Outcome and Relative Risk in Women With Atypical Squamous Cells of Undetermined Significance

SCREENING FOR CERVICAL CANCER: REVISED

Streamlining Protocols-From Strategy to Implementation. Doreen Ramogola-Masire Botswana UPenn Partnership June 2014

Human Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?

Utility of Pap Smear in Cervical Screening in a Tertiary Care Hospital

PAP smear. (Papanicolaou Test)

New Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology

Cervical Screening Results Leading to Detection of Adenocarcinoma in Situ of the Uterine Cervix

Prepared By Jocelyn Palao and Layla Faqih

Taking Laboratory Coding for a Spin. Corrie Alvarez, CPC, CPMA, CPC-I, CEDC

Outcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells

The Bethesda System: Updates for th Cytopathology Congress Bursa, Turkey October 14, 2015

2016 myresearch Science Internship Program: Laboratory Medicine. Civic Education Office of Government and Community Relations

I have no financial interests in any product I will discuss today.

SOGC / SCC Clinical Practice Guideline

Your Colposcopy Visit

Hyperchromatic Crowded Groups: What is Your Diagnosis? Session 3000

Department of Health Standard for the Cervical Cancer Screening Program. Approval Date: 08 May 2018 Effective Date: 13 May 2018

Department of Obstetric and Gynecology, Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey

Study of Cervical Pap Smears in a Tertiary Hospital

Liquid-Based Cytology New Possibilities in the Diagnosis of Cervical Lesions

From the Department of Pathology, King Abdulaziz University Hospital, Jeddah, Saudi Arabia

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal

JMSCR Vol 07 Issue 02 Page February 2019

INTRODUCTION HSIL AND CERVICAL CARCINOMA IN ASCUS CERVICAL CYTOLOGY

Cervical Cancer 4/27/2016

Cytology and Surgical Pathology of Gynecologic Neoplasms

Case 3 - GYN. History: 66 year old, routine Pap test. Dr. Stelow

WELL WOMAN CLINIC-SCREENING PROGRAM FOR CERVICAL CARCINOMAS G. J. Vani Padmaja 1

Transcription:

Citološka klasifikacija i n t r a e p i t e l n i h lezija vrata maternice mr.sc. Ovanin - Rakić Ana, dr.med. 1953 otvoren prvi laboratorij za ginekološku citologiju u Hrvatskoj u Petrovoj 1954 Papanicolaou-ova numerička klasifikacija 1968 modifikacija Papanicolaou-ove klasifikacije dodavanjem dijagnoza sukladnih histološkom nazivlju 1990 nova klasifikacija Zagreb 1990 modifikacija The 1988 Bethesda System 2002 Zagreb 2002 modifikacija Zagreb 1990 i NCI Bethesda 2001 Zagreb 2002 Ovanin-Rakić, Pajtler, Stanković i sur 1

Pločasti epitel 1954 Papanicolaou n u m e r i č k a I - V 2

1968 Zagreb Audy, Ivić Singer modifikacija klasifikacije po Papanicolaou predviđanje numerička + histološke dijagnoze Promjene nazivlja i klasifikacije intraepitelnih lezija pločastog epitela 1961. Wien 1969. Richart, Barron Dysplasia levis 1980. Richart 1988. Bethesda Dysplasia levis Dysplasia media Dysplasia gravis Carcinoma in situ Dysplasia media CIN I CIN CIN II III CIN IV Dysplasia gravis CIN I CIN II CIN III SIL SIL I II CIN - cervikalna intraepitelna neoplazija ( Bethesda 1973 ) Carcinoma in situ SIL - skvamozna intraepitelna lezija 3

Bethesda 1988 Squamous Cells Atypical squamous cells of undetermined significance ( ASCUS ) Squamous intraepithelial lesions ( SIL ) Low - grade SIL HPV associated changes, mild dysplasia / CIN 1 High - grade SIL moderate dysplasia / CIN 2 severe dysplasia / CIN 3 carcinoma in situ / CIS Sporne točke Bethesd ethesde 1988 Raspoložive metode liječenja u nas kasnih 80-tih s mogućim posljedicama za SIL Dvije reprodukciju skupine Modifikacija DM Bethesda 1988 SIL visokog Zagreb stupnja 1990 (u primjeni od 1993.) DM Dysplasia media Squamous cell carcinoma Bethesda 1988 Squamous Cells Zagreb 1990* Skvamozne stanice Atypical squamous cells Abnormalne skvamozne stanice neodređenog of undetermined significance ( ASCUS ) značaja aja Squamous intraepithelial lesions ( SIL ) Low - grade SIL HPV associated changes, mild dysplasia / CIN 1 High - grade SIL moderate dysplasia / CIN 2 severe dysplasia / CIN 3 carcinoma in situ / CIS Squamous cell carcinoma Skvamozne intraepitelne lezije ( S I L ) Dysplasia levis Dysplasia media Dysplasia gravis Carcinoma in situ CIN I CIN II CIN III Plus promjene povezane s HPV Carcinoma planocellulare SIL niskog stupnja SIL visokog stupnja * Audy-Jurkovi Jurković, Singer, Pajtler et al 4

ASCUS Atipične skvamozne stanice neodređenog značenja Abnormalnosti stanice koje su izrazitije od onih kod reaktivnih promjena,a kvantitativno i kvalitativno su nedovoljne za dijagnozu skvamoznih intraepitelnih lezija Kurman, Solomon 1994 Bethesda 2001 Squamous Cell Atypical squamous cells ( ASC ) of undetermined significance ( ASC - US ) cannot exclude HSIL ( ASC - H ) Squamous intraepithelial lesions ( SIL ) ASC -US ASC-HPočetna invazija? Low-grade squamous intraepithelial lesion ( LSIL ) HPV, mild dysplasia / CIN 1 High-grade grade squamous intraepithelial lesion ( HSIL ) moderate and severe dysplasia, CIS / CIN2, CIN3 with features suspicious for invasion Squamous cell carcinoma Zagreb 2002 * Skvamozne stanice Atipične skvamozne stanice ( ASC ) neodređenog značenja ( ASC - US ) ne može e se isključiti iti HSIL ( ASC - H ) ne može e se isključiti iti invazija Skvamozne intraepitelne lezije ( SIL ) Dysplasia levis CIN 1 Low-grade SIL Dysplasia media CIN 2 Dysplasia gravis High-grade grade SIL Carcinoma in situ CIN 3 Plus promjene povezane s HPV Početna invazija se ne može e isključiti iti Carcinoma planocellulare * Ovanin-Raki Rakić, Pajtler, Stanković et 5

Cilindrični ni epitel Bethesda 1988. Glandular Cells Presence of endometrial cells in one of the following circumstances Out - of - phase in a menstruating woman In a postmenopausal woman No menstrual history available Atypical glandular cells of undetermined significance (AGCUS) Endometrial Endocervical Not other specified Adenocarcinoma Specify probable site of origin : endocervical, endometrial, extrauterine Not other specified Zagreb 1990. (Audy, Singer, Pajtler) Cilindrične stanice Abnormalne cilindrične stanice neodređenog značenja Endometrijske Endocervikalne Neodređenog porijekla Adenocarcinoma Endometrija Endocerviksa Ekstrauterini Neodređenog porijekla 6

AGCUS Atipične cilindrične stanice neodređenog značenja Atipija jezgre endometralnih ili endocervikalnih cilindričnih stanica koja je izrazitija od reaktivnih ili reparativnih promjena, a bez jasnih značajki za invazivni adenokarcinom Kurman, Solomon 1994 AGCUS - podjela neklasificirane vjerojatno reaktivne vjerojatno premaligne / maligne Revizija Bethesda 1988, 1991. 7

Bethesda 2001 Glandular Cell: Atypical glandular cells (AGC) endocervical cells ( NOS or specify in comments ) endometrial cells ( NOS or specify in comments ) glandular cells ( NOS or specify in comments ) Atypical glandular cells endocervical cells, favor neoplastic glandular cells - NOS, favor neoplastic Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma endocervical, endometrial, extrauterine not otherwise specified ( NOS ) Zagreb 2002 (Ovanin, Pajtler, Stanković i sur.) Glandularne stanice: Atipične glandularne stanice (AGC) Vjerojatno reaktivne promjene Vjerojatno intraepitelna lezija Vjerojatno invazivna lezija Adenocarcinoma in situ (AIS) Adenocarcinoma Porijeklo: Endocervikalne Endometralno Ekstrauterino Neodređeno Zagreb 2002 (Ovanin, Pajtler, Stanković i sur.) Glandularne stanice: Atipične glandularne stanice (AGC) Vjerojatno reaktivne promjene Vjerojatno intraepitelna lezija Vjerojatno invazivna lezija Adenocarcinoma in situ (AIS) Adenocarcinoma Porijeklo: Endocervikalne Endometralno Ekstrauterino Neodređeno BROJ ABNORMALNIH STANICA TIP DESKVAMACIJE JEZGRA - oblik, veličina, kromatin nukleoli, mitoze POZADINA RAZMAZA 8

Zagreb 2002 (Ovanin, Pajtler, Stanković i sur.) Glandularne stanice: Atipične glandularne stanice (AGC) Vjerojatno reaktivne promjene Vjerojatno intraepitelna lezija Vjerojatno invazivna lezija Adenocarcinoma in situ (AIS) Adenocarcinoma Porijeklo: Endocervikalne Endometralno Ekstrauterino Neodređeno Zagreb 2002 (Ovanin, Pajtler, Stanković i sur.) Glandularne stanice: Atipične glandularne stanice (AGC) Vjerojatno reaktivne promjene Vjerojatno intraepitelna lezija Vjerojatno invazivna lezija Adenocarcinoma in situ (AIS) Adenocarcinoma Porijeklo: Endocervikalne Endometralno Ekstrauterino Neodređeno 9

Zagreb 2002 (Ovanin, Pajtler, Stanković i sur.) Glandularne stanice: Atipične glandularne stanice (AGC) Vjerojatno reaktivne promjene Vjerojatno intraepitelna lezija Vjerojatno invazivna lezija Adenocarcinoma in situ (AIS) Adenocarcinoma Porijeklo: Endocervikalne Endometralno Ekstrauterino Neodređeno ADENOCa -diferencijalna dijagnoza REPARATORNI EPITEL POSTRADIJACIJSKE PROMJENE DECIDUALNA REAKCIJA PROMJENE KOD IUD a KARCINOM ( nekeratinizirani pločasti, anaplastični, endometralni, metastatski) ENDOCERVICITIS MIKROGLANDULARNA HIPERPLAZIJA TUBARNA METAPLAZIJA (endometrioidni tip) UZORAK UZET ČETKICOM NAKON KONIZACIJE ( BETTENDORF U.; BOON ME; SUURMEIJER 1991. g. ) 10

Z a k lj u č a k CIN II ( DM ) izdvajanjem iz HSIL u Zagreb 1990 i 2002 drugačiji dg.- th. postupnik ASC i AGC podjela na tri podskupine kraći i adekvatniji put do konačne dijagnoze AIS uvršten u klasifikaciju kao zasebna dijagnoza Zagreb 1990 i 2002 jedinstvene klasifikacije za cijelu Hrvatsku Prevalencija i histološka provjera atipičnih stanica (ASC i AGC) Barišić Ana, dr.med 11

Prevalencija (%) ASC AGC Dozvoljena * 5 1,8 KB Osijek, KB Rijeka, KBC Zagreb Petrova III / 1999 0,09-7,3 0,06-1,6 KBC Zagreb Petrova ( 2005.god.) 6,50 1,63 Literatura ** 1,0-10,32 0,11-2,10 * Kurman, Solomon 1994 ** Davey i sur 1996, Bergeron i sur 2000, Ferreccio i sur 2003, Chhieng i sur 2004, Kennedy i sur 1996, Korn i sur 1998, Manetta i sur 1999, Burja i sur. 1999, Histološka provjera - teža a lezija ( % ) ASC AGC 10 20 CIN 2/3 intraepitelne 9,8-34,9-88 % pločasti epitel (skvamozne ili glandularne) 0,1-1,7 % invazija invazivne 4-12,7 invazija - 97% cilindrični epitel ( pretežno endometralni ) Solomon i sur 2001 Eltabbakh Eddy i sur i 1997 sur 2000, Soofer, Sidawy 2000, Eddy i sur 1997, De Simone i sur, 2006 12

Zavod za ginekološku citologiju Petrova (2005. god 27 725 VCE obrisaka) ASC (1803/ 6,50%) ASC-US (1511/ 5,45%) ASC-H (246/ 0,88%) ASC-inv? (46/ 0,17%) H I S T O L O Š K A P R O V J E R A 1 /0,06% 14 /5,69% CIN I ASC-H (11) ASC-H + ACG II/III (3) CIN II 2 CIN III 8 CIM 1 0 / 0% CIN III + AIS 2 Carcinoma Adenosquamosum (biopsija) 1 (Planocelulare trajni PHD) Zavod za ginekološku citologiju Petrova (2005. god 27 725 VCE obrisaka) AGC (450/ 1,63%) H I S T O L O Š K A P R O V J E R A vjerojatno reaktivno (362/ 1,31%) vjerojatno intraepitelno (63/ 0,23%) 4 /6,35% Intraepitelne lezije 100% (4) CIN III, AIS 2 AIS 1 CIN III 1 vjerojatno invazivna (25/ 0,09%) 5 /20,0% Invazivne lezije 100% (5) AC endometrija 3 AC cerviksa 1 IC početna inv. 1 13